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ABSTRACT  
 
Cutaneous melanoma has an aggressive clinical presentation with rapid growth velocity 
and metastatic dissemination. To evaluate prognostic factors and survival of patients 
diagnosed with primary cutaneous melanoma. Clinical-epidemiological and 
histopathological data from 102 patients diagnosed between 2004 to 2008, were retrieved 
from the archives of the Pathological Anatomy Service of the Araújo Jorge Hospital in 
Goiânia, Goiás, Brazil. For survival analysis, we selected patients who underwent a 60-
month follow-up. Cutaneous melanoma affects mostly female individuals with the age of 
diagnosis ranging from 51 to 70 years. Regarding the clinical evolution of the patients 
63.7% were alive during this study, and 25.5% died of melanoma. Metastasis were present 
in 47% of patients and 70.8% grew in the lymph nodes. The overall survival curve 
regarding the 5-year follow-up was 73%. The study group with Breslow index ≥2.1mm 
(p=0.0339), level of Clark IV and V (p=0.0007) and the presence of metastasis presented 
a lower survival rate. Early diagnosis emphasizing the significant prognostic factors of 
patients with cutaneous melanoma allows the definition of prognostic with a more reliable 
estimate and more survival probabilities. 
Keywords: Melanocytes; Neoplasm Metastasis; Risk Factors; Skin Neoplasms. 
RESUMO 
O melanoma cutâneo apresenta apresentação clínica agressiva com rápida velocidade de 
crescimento e disseminação metastática. Avaliar fatores prognósticos e sobrevida de 
pacientes com diagnóstico de melanoma cutâneo primário. Dados clínico-
epidemiológicos e histopatológicos de 102 pacientes diagnosticados no período de 2004 
a 2008 foram extraídos dos arquivos do Serviço de Anatomia Patológica do Hospital 
Araújo Jorge de Goiânia, Goiás, Brasil. Para análise de sobrevida, selecionamos pacientes 
que foram submetidos a um seguimento de 60 meses. O melanoma cutâneo acomete 
principalmente indivíduos do sexo feminino com idade de diagnóstico variando de 51 a 
70 anos. Em relação à evolução clínica dos pacientes, 63,7% estavam vivos durante este 
estudo e 25,5% morreram de melanoma. Metástases estavam presentes em 47% dos 
pacientes e 70,8% cresceram nos linfonodos. A curva de sobrevida global em relação ao 
seguimento de 5 anos foi de 73%. O grupo estudo com índice de Breslow ≥ 2,1 mm (p = 
0,0339), nível de Clark IV e V (p = 0,0007) e a presença de metástase apresentaram menor 
taxa de sobrevida. O diagnóstico precoce enfatizando os fatores prognósticos 
significativos dos pacientes com melanoma cutâneo permite a definição de prognóstico 
com uma estimativa mais confiável e mais probabilidades de sobrevida. 
Palavras-chave: Melanócitos; Metástase Neoplásica; Fatores de risco; Neoplasias 
Cutâneas. 
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1 INTRODUCTION 
Skin cancer is the most prevalent neoplasia in the world. Cutaneous melanoma 
has an aggressive clinical presentation with rapid growth velocity and metastatic 
dissemination. Although it represents approximately 4% of all skin cancer, it shows a 
high lethality being responsible for 60% of all the deaths by cutaneous neoplasia (1,2). 
Shows a slightly higher frequency in females, which also presents a better prognosis and 
is uncommon in children, affecting predominantly middle-aged adults (3,4).  
In most cases melanoma develops as an intraepidermal proliferation of neoplastic 
melanocytes that may be kept isolated in the epidermis or superficial dermis (5,6). At this 
stage of development, the melanoma has a high rate of cure through a proper surgical 
excision. The essential biological characteristics of the radial growth phase of melanoma 
appear slowly but with intense proliferation of atypical cells in the epidermis with 
possible neoplastic migration to the dermal papillae (7,8). In advanced stages, such as the 
vertical growth phase, the lesion may form nodules and infiltrate the reticular dermis 
reaching hypodermis (9,10). At this point, the lesions can metastasize and its prognosis 
is directly related to the depth of invasion (11,12). 
The Breslow index is still the most important prognostic factor for melanoma (13). 
According to the tumor progression, from melanocyte hyperplasia to melanoma, there are 
five histologically distinct stages characterized by common nevi, atypical nevi, radial 
growth melanoma, vertical growth melanoma and metastatic melanoma (6). However, 
most cutaneous melanomas do not originate from melanocytic nevi, but as a de novo 
melanoma. This suggests that most melanomas do not follow this specific model of 
progression (1,9,11). 
The knowledge of the epidemiology and pathogenesis of cutaneous melanoma 
provides subsidies for the application of primary and secondary preventive measures, 
which are fundamental to determine public health strategies. Melanoma may have a good 
prognosis if it is not thick, with cure rates approaching 100% for in situ melanomas 
Ferreira2016. When the diagnosis is made from the Breslow index and exceeds 4mm, 
survival falls to less than 50% in a five years’ time (14). Unlike most other tumors in 
which a tumor of 2mm to 3mm is at early stages, this size of tumor is already considered 
advanced regarding melanomas and show great lethality (8,15). In these cases, the 
surgical treatment after the early diagnosis is the only chance of cure. Therefore, this 
study evaluated the prognostic factors and survival of patients diagnosed with primary 
cutaneous melanoma. 
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2 METHODS 
This is a retrospective study of clinical-epidemiological and histopathological data 
from 102 patients diagnosed with primary cutaneous melanoma. We retrieved data from 
the archives of the Pathological Anatomy Service of the Araújo Jorge Hospital (AJH) in 
Goiânia, Goiás, Brazil, during the period 2004 to 2008. For survival analysis, we selected 
patients who underwent a 60-month follow-up. We verified the death records from the 
Brazilian Mortality Information System and included patients whom melanoma was the 
cause of death. 
Data were collected from medical records and histopathological reports with 
information regarding age, date of diagnosis, tumor location, family history of melanoma, 
histological type (superficial spreading melanoma, nodular melanoma, lentigo maligna, 
acral-mucosal melanoma or unclassifiable), regression, ulceration, peritumoral 
lymphocytic infiltration, mitotic index, microscopic satellites, Breslow tumor thickness, 
Clark level, regional lymph node involvement, margin involvement, distant metastasis 
and patient follow-up. We excluded incomplete medical records from the study. Tumors 
were classified according to the World Health Organization for cutaneous melanoma 
(International Classification of Diseases 10-C43). 
The categories were found to be associated through the use of Chi-squared and 
Fisher’s tests. Survival curves were estimated using the Kaplan‐Meier method and 
compared using the log‐rank test. P< 0.05 was adopted as significant. SPSS® for 
Windows® (version 16.0) in order to perform statistical analysis. This study was 
submitted and approved by the Associação de Combate ao Câncer em Goiás (ACCG) and 
Universidade Federal de Goiás (UFG) Ethics and Research Committee. 
 
3 RESULTS 
The study population consisted of 62.7% females (64/102) and 37.3% males 
(38/102). The mean age observed for men was 63.1 years (SD ± 17.0) and women was 
57.2 years (SD ± 17.3). The age difference between the groups and the most prevalent 
age group ranged from 51 to 70 years old (44.1%) (p<0.0026). However, there was a 
patient diagnosed at the age of 13 years old. We found statistically significant difference 
regarding the gender of the patients and the age group at the time of diagnosis (p<0.023) 
(Table 1). 
The torso was the primary site most affected by cutaneous melanoma, affecting 
32.3% of patients. Regarding the family medical history 70.6% of patients reported no 
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cases in the family and 10.8% reported cases of melanoma in the family. We found that 
superficial spreading melanoma was present in 52.9% of patients. The Breslow index 
(thickness of the tumor), the highest prevalence was ≤1.0mm, present in 39.2% of the 
cases, followed by injuries deeper than >4.0mm, present in 23.5% of patients. According 
to the Clark level, 29.4% of patients were level IV and 25.5% were level V. Ulceration 
was present in 45.1% and absent 54.9% of the samples. Tumor regression was observed 
in 11.8% and absent in 82.2%. The mitotic index was present in 91.2% of the samples 
and the peritumoral lymphocyte infiltration in 91.2%. Microscopic satellite was absent in 
87.3% of the tumors evaluated and histopathological evaluation showed that 98% were 
tumor-free margin (Table 2).  
Metastasis occurred in 47% of the cases. Regarding the clinical evolution of the 
patients, 63.7% were alive during this study, 25.5% died of melanoma and 10.8% died 
due from other causes, such as acute myocardial infarction (Table 2). Distant metastasis 
was present in 47% of patients during the five years period of the study (60 months) and 
70.8% grew in the lymph nodes, 27.1% in the lungs and skin, 18.8% in the brain, 10.4% 
in the bones, 6.3% in the liver and the remaining 4.2% in the stomach (Figure 1). The 
sites of metastasis repeated two or three times in different locations such as lymph node 
and skin, lymph node, lung and brain. 
The overall survival curve regarding the 5-year follow-up (60 months) was 73% 
(Figure 2). Survival rate for patients with cutaneous melanoma compared to the Breslow 
index ≤2mm was 82.3% and 64.1% for index ≥2.1mm (p=0.0339) (Figure 3). The 
survival rate for patients with cutaneous melanoma regarding the Clark level was 91.3% 
for levels I, II and III, and 62.5% for levels IV and V (p=0.0007) (Figure 4). The survival 
rate for cutaneous melanoma patients according to the development of metastasis was 
58.3% for patients who develop metastasis and 90.7% for those who did not (p=0.0007) 
(Figure 5). 
 
4 DISCUSSION 
Melanoma prognosis is based on clinical and histopathological factors. The first 
step in developing strategies for disease prevention is to assess the magnitude of the 
problem and the characteristics of the affected population (1,6). In Brazil, 
epidemiological data are scarce. 
According to the Brazilian National Cancer Institute (INCA) there are 6,260 new 
cases per year with 2,920 men and 3,340 women with cutaneous melanoma in Brazil in 
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2018 and 1,547 cases of death (903 men and 644 women) (16). The population-based 
cancer registries in Brazil, the city of Goiânia has the highest percentage of cases 
calculated by the standardized incidence coefficient (SIC) for invasive cutaneous 
melanoma among men (8.1/100,000). Among women, the highest SIC for invasive 
cutaneous melanoma is found in Goiânia (6.1/100,000) (1,17). 
In this study 62.7% of the patients were female. The number of patients was more 
restricted due to 60-month follow-up within the period 2004-2008. Most melanoma 
studies performed in Brazil showed a prevalence of women patients, although few studies 
comprised a group of patients where males were more prevalent (1,15,18,19,20,21,22). 
Other studies did not found difference regarding gender and cutaneous melanoma in a 
study conducted in Goiânia, Goiás, Brazil (23).  
The different study period may justify this change in the incidence of melanoma 
between men and women. Moreover, women seek medical attention more often, 
especially regarding dermatological care. This fact may be a possible explanation for the 
predominance of women in the sample group. Also, social inequalities and health policies 
explains the difference of health policies directed to women in Brazil and along with the 
lower participation of men in healthcare, generate important differences (9,10,12). 
Brazil is a tropical country, with high temperatures during most of the year, thus it is 
expected that there will be greater sun exposure of people during life (15,17). Goiania is 
located in Brazil’s Midwestern region, at an average altitude of 749 meters and latitude -
16°40’43’’. It’s observed to have high and very high ultraviolet radiation rates in the fall 
and in the winter, and extreme ones in the spring and in the summer, according to National 
Institute for Space Research (INPE) (12). 
In Brazil, skin cancer is the most incident, and melanoma is more aggressive than 
other types of this cancer. In the world, the cutaneous melanoma types are registered in 
countries with Caucasian population, while lower rates are commonly found in South 
American countries, where and Afro-American populations and pardos (triracial 
descendants of Europeans, Native Americans, and West Africans) predominate, as in 
Brazil (12,17).  
The age of cutaneous melanoma diagnosis is related to prognosis and the higher 
the age the lower the survival of the patient (20). The mean age observed in this study 
was 57.2 years for women and 63.1 years for men (p<0.0026), and the age of diagnosis 
ranged from 51 to 70 years (44.1%). The mean age of cutaneous melanoma diagnosis in 
Goiânia was found averages of 54-60 years old. Despite the consistency of the results, it 
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is unclear why melanoma shows a tendency to increase the rate of diagnosis in middle-
aged adults (1,15,21,23,24). A possible explanation is the cumulative effect of solar 
radiation besides deterioration of the immune system, DNA damage and DNA repair 
failures (10,25,26). 
The primary site most affected by cutaneous melanoma was the torso (32.3%), 
followed by the lower limbs (24.5%). This confirms the relationship between the 
occurrence of cutaneous melanoma and exposure to solar radiation since its higher 
incidence affect areas more exposed to sun radiation. Most authors consider the torso the 
site of melanoma occurrence with the worst prognosis (19,27,28). Melanoma located in 
the head, neck and torso show the worst prognosis, and a lower survival rate of patients 
with lesions in their hands and feet (4,5,8).  
A family history of melanoma is an important risk factor. Patients with cutaneous 
melanoma in first-degree relatives have twice the risk of developing cutaneous 
melanoma, while three or more family members with melanoma may increase the risk by 
35 to 70 times (8,9,24,25). A family history of melanoma was present in 18.6% of 
patients. 
The histological type of cutaneous melanoma most found was the superficial 
extensive melanoma (52.9%) followed by nodular melanoma (25.5%) associated with 
thicker tumors. Superficial extensive melanoma is predominant in Caucasians, followed 
by the nodular type, the lentigo maligna and the acral type (12,20). However, some studies 
show a predominance of the nodular type over the superficial extensive melanoma likely 
due to the ethnic differences of the extensive miscegenation in the Brazilian population 
(9,29). 
The Breslow index, the highest incidence was tumors ≤1mm (39.2%) followed by 
lesions >4mm (23.5%). Considering the depth of the lesion, a large number of tumors 
showed thickness above 4mm. Araújo Jorge Hospital is a reference in oncology in the 
State of Goiás and the most serious and complex cases are referred to this institution. 
Studies found an increase in the incidence of thin melanoma (up to 1mm thick) compared 
to thick melanomas (greater than 3.5mm) (5,11,30). The increased incidence of thin 
melanoma is due to an early diagnosis, which leads to an improvement in survival rates 
(13). In Goiânia, Sortino-Rachou et al. found 2.8% melanoma in situ, and Fernandes et 
al. showed lower rates of in situ melanoma diagnosis (2.5%), which corroborates our 
results (23,31). 
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Today, a new concept that the density of melanoma cells at the position where 
Breslow thickness is measured is a morphological prognostic biomarker, which called 
Breslow density. This represents a novel morphological prognostic biomarker that is 
independent of Breslow thickness and has prognostic value for overall survival (2,11,13). 
In this study, the level of Clark IV corresponded to 29.4% followed by level V with 
25.5%. The Clark level was initially an independent prognostic factor, such as the 
Breslow index. The American Joint Committee on Cancer (AJCC) stated in 2002 that the 
Clark level evaluate the prognosis of lesions when the Breslow index is <1mm. Currently, 
Clark’s level evaluates thin melanomas (≤1mm) only when information on the mitotic 
index is not available (5,32). 
Ulceration is a histological feature associated with the strong aggressiveness of 
cutaneous melanoma. Ulceration was present in 40.2% of the analyzed samples. The 
survival rate of patients with ulcerated melanoma is proportionally worse compared to 
those without ulceration. The rate of ulcerated melanoma is about 35% for patients with 
localized disease and 6% for thin melanoma (32). Melanoma staging was the variable that 
most influenced the 10-year survival in patients with localized melanoma based on 
Breslow thickness and ulceration. 
The mitotic index was present in 91.2% of the samples. Borges et al. showed the 
presence of mitoses aggravates the prognosis of patients with melanoma (20). A 
multivariate analysis of 10,233 melanoma patients reported that mitotic index is the 
second most important prognostic factor and tumor thickness based on Breslow index is 
the primary factor (32,33). The most significant correlation with survival was at a rate of 
at least one mitosis per cubic millimeter. The presence of mitoses is correlated with the 
reduction of disease recurrence time (28). Mitotic index influenced tumor thickness and 
ulceration but was not significant to patient survival. 
About the distant metastasis onset 47% of the patients developed metastasis within 
the five-year follow-up period. Among, 70.8% of metastasis were in the lymph nodes, 
27.1% in the lungs and skin, 18.8% in the brain, 10.4% in the bones, 6.3% in the liver 
and 4.2% in the stomach (figure 1). Approximately two-thirds of the initial metastasis 
will be limited to the drainage area of lymph nodes, making them the most common site 
of better metastatic cells survival. Distant metastasis may have a non-visceral character 
affecting skin, subcutaneous tissue and non-regional lymph node or a visceral character 
affecting mainly lungs (18-36%), followed by liver (14-20%), brain (12-20%), bone (11-
17%) and gastrointestinal tract (1-7%) (14,32).  
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Non-visceral metastasis usually has a better prognosis when compared to visceral 
metastasis. Metastatic melanoma of an unknown primary site accounts for 2% to 5% of 
the cases and in 60% of the times lymph nodes are involved. Other sites affected are skin 
and subcutaneous tissue, less frequently the lung, brain and gastrointestinal tract (4,7,34). 
For metastatic disease, the presence and characteristics of lymph nodes and distant 
metastases are the major factors impacting survival. 
About the clinical evolution of the patients in this study 25.5% died from 
melanoma. Studies there is an improvement in the survival rate of patients with cutaneous 
melanoma in recent years, which is attributed to an early diagnosis (6,33,35). Mortality 
rates declined in men and women younger than 65 years but increased for older 
individuals with cutaneous melanoma (6.6% for men and 0.6% for women) (34,35,36). 
The overall survival curve with a 5-year follow-up of patients was 73%. Other 
studies with melanoma patients in Goiânia found an equal result (73% and 81.4%) 
(23,37). The patients evaluated in this study were observed from the moment of diagnosis, 
which was confirmed by histopathological report, until the moment they left the study 
either by death or by last outpatient contact (12,17). Further analysis including more years 
and more patients is required. 
In the present study, mortality rate was higher with for higher Breslow index, 
Clark’s level and the presence of metastasis. Statistical analysis was significant when 
comparing melanoma mortality between the different levels of Breslow (p=0.0339), Clark 
(p=0.0007) and metastasis (p=0.0007), revealing a higher severity of the disease among 
patients. Survival rates for cutaneous melanoma patients compared to the Breslow index 
≤2mm were 82.3% and 64.1% for Breslow index ≥2.1mm (p=0.0339). The risk increased 
linearly with tumor thickness up to a depth of 6mm from when the risk reaches a plateau 
(11,13,36,38).  
In this study Clark level increase was directly related to the risk of death. The 
Clark levels I, II and III were 91.3% and levels IV and V were 62.5% (p=0.0007). 
Increasing Clark levels influenced the occurrence of melanoma deaths in patients with 
localized tumor, regardless of age, location of tumor, ulceration and tumor thickness. The 
level of Clark IV and V was associated with an increased risk of metastasis in the sentinel 
lymph node in patients with thick melanomas (>4mm) (38,39). Clark level V melanoma 
showed a 14-fold greater risk of death over 10 years than those with Clark level I 
melanoma (p<0.0001) (38).  
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In melanomas with thickness between 1mm and 2mm, the Clark level did not 
influence the occurrence of lymph node metastasis, the distance of metastasis neither the 
survival rate of patient (39). The survival rate of the individuals with and without 
metastasis was 58.3% and 90.7%, respectively (p=0.0007). Metastasis indicate a worse 
prognosis, with survival estimates assessed in months. Several studies found a shorter 
survival rate in individuals with metastatic melanoma (40,41,42,43,44). 
 
5 CONCLUSION 
Data from Brazil of melanoma patients and prognostic factors remain scarce. In 
this study cutaneous melanoma affects mostly female individuals with the age of 
diagnosis ranging from 51 to 70 years. The study group with Breslow index ≥2.1mm, 
level of Clark IV and V and the presence of metastasis presented a lower survival rate.  
This study shows that Brazilian melanoma patients experienced a lower survival rate than 
the current worldwide average. Evidencing the importance of an early diagnosis and 
emphasizing the significant prognostic factors of patients with cutaneous melanoma 
investigated in the present study allows the definition of prognostic groups with a more 
reliable estimate and allowed the calculation of survival probabilities. The increasing 
number of qualified professionals, prevention campaigns and sun protection tend to 
provide better early detection rates of the disease. This study showed an analysis of the 
population seen in our hospital, which is reference for the treatment of melanoma in 
Goiânia, Goiás, Brazil. 
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ANEXOS 
 
Figure 1: Distribution of the main sites of distant metastasis among patients with cutaneous melanoma. 
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Figure 2: Kaplan-Meier curves illustrating overall 5-year (60-month) survival rate of cutaneous 
melanoma patients. 
 
 
 
Figure 3: Kaplan-Meier curves illustrating 5-year (60-month) survival rate regarding the Breslow index 
for patients with cutaneous melanoma. 
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Figure 4: Kaplan-Meier curves illustrating 5-year (60-month) survival rate regarding the Clark’s level for 
patients with cutaneous melanoma. 
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Figure 5: Kaplan-Meier curves illustrating overall 5-year survival (60 months) rate regarding metastatic 
development for cutaneous melanoma patients. 
 
 
Table 1: Distribution of melanoma cases according to gender and age of the patients at the time of 
diagnosis in an oncological reference center. 
 
GENDER FEMALE MALE TOTAL p 
n (%) 64 (62.7) 38 (37.3) 102 (100) 
0.0026 
Average age (±SD) 57.2 (± 17.3) 63.1 (± 17.0) 59.4 (± 17.3) 
Age group at diagnosis n (%) n (%) n (%)  
10-30 7 (10.9) 0 (0) 7 (6.9) 
0.023 
31-50 17 (26.6) 5 (13.2) 22 (21.5) 
51-70 22 (34.4) 23 (60.5) 45 (44.1) 
71-90 17 (26.6) 10 (26.3) 27 (26.5) 
91-100 1 (1.5) 0 (0) 1 (1.0) 
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Table 2: Clinical and histopathological characteristics of patients diagnosed with cutaneous melanoma, in 
an oncological reference center. 
VARIABLES CATEGORY % 
Primary local 
Torso 32.3 
Lower limbs 24.5 
Face / Scalp 18.6 
Upper limbs 13.8 
Palmoplantar 9.8 
Cervical 1 
Family history of melanoma 
Yes 10.8 
No 70.6 
No information 18.6 
Histological type 
Extensive Superficial 52.9 
Nodular 25.5 
Acral 9.8 
Lentigo maligna 6.9 
Unclassifiable 4.9 
Breslow’s index 
In situ 1 
≤ 1.0 mm 39.2 
1.01 a 2.0 mm 21.6 
2.01 a 4.0 mm 14.7 
> 4.0 mm 23.5 
Clark’s level 
I 1 
II 23.5 
III 20.6 
IV 29.4 
V 25.5 
Ulceration 
Present 45.1 
Absent 54.9 
Regression 
Present 11.8 
Absent 82.2 
Mitotic Index 
Present 91.2 
Absent 8.8 
Present 91.2 
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Peritumoral Lymphocyte 
Infiltration 
Absent 8.8 
Microscopic Satellite 
Present 12.7 
Absent 87.3 
Positive margins 
Present 2 
Absent 98 
Metastasis 
Present 47 
Absent 53 
Progression 
Alive 63.7 
Died from melanoma 25.5 
Died from other causes 10.8 
 
